Teliso-v in combination with osimertinib exhibited robust efficacy alongside a manageable safety profile in patients with EGFR-mutated advanced/metastatic NSCLC harboring c-Met overexpression in a Phase I/Ib trial[75,76]. Here, MET is linked to non-small cell lung carcinoma.